Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

6.51USD
3:59pm EST
Change (% chg)

$-0.12 (-1.81%)
Prev Close
$6.63
Open
$6.60
Day's High
$6.67
Day's Low
$6.50
Volume
78,585
Avg. Vol
90,914
52-wk High
$7.24
52-wk Low
$2.26

Select another date:

Thu, Nov 9 2017

BRIEF-ChromaDex Corp qtrly ‍reported net sales of $6.1 million from continuing operations

* Chromadex Corp - qtrly ‍reported net sales of $6.1 million from continuing operations compared to $3.9 million for Q3 of 2016​ Source text: (http://bit.ly/2zpFLpg) Further company coverage:

BRIEF-ChromaDex Q3 loss per share $0.07 from continuing operations

* Q3 sales rose 55 percent to $6.1 million Source text for Eikon: Further company coverage:

BRIEF-Chromadex announces $23 mln private placement of common stock

* Chromadex announces $23 million private placement of common stock

BRIEF-Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 mln

* Chromadex Corp files for common stock‍​ offering by selling stockholders of up to $7.7 million - SEC filing Source text: [http://bit.ly/2z2cq3P] Further company coverage:

BRIEF-Chromadex announces top-line results of its second human clinical trial

* Chromadex announces top-line results of its second human clinical trial

BRIEF-ChromaDex Partners with Watsons, for TRU NIAGEN retail launch

* ChromaDex Corp - new partnership with Hong Kong based retailer, A.S. Watson, for launch of U.S. Made TRU NIAGEN) dietary supplement in Asia Source text for Eikon: Further company coverage:

BRIEF-Chromadex's units enter asset purchase agreement with Covance Laboratories Inc​

* Chromadex Corp - ‍on august 21, 2017, co's units entered into an asset purchase agreement with Covance Laboratories Inc​

BRIEF-Chromadex sells its analytical testing business to LabCorp

* Chromadex sells its analytical testing business to LabCorp, to accelerate the expansion of Nicotinamide Riboside and its other patented ingredient technologies

BRIEF-Chromadex announces closing of final tranche of $25 mln strategic investment and appoints two new board members

* Chromadex announces closing of third and final tranche of the $25 million strategic investment led by Mr. Li Ka-shing and appoints two additional board members

BRIEF-ChromaDex Q2 loss per share $0.07

* Q2 loss per share $0.07 Source text for Eikon: Further company coverage:

Select another date: